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Translational relevance
Mitotane is the reference drug in the management of adrenocortical carcinoma (ACC) and is increasingly prescribed in an adjuvant setting. Serum mitotane levels are the only known predictive factor of efficacy. In the present paper, we observed in two independent series of radically resected ACC patients, that in patients with low ribonucleotide reductase large subunit 1 (RRM1) gene expression adjuvant mitotane was associated with improved disease free survival, whereas this effect was lost in cases with high RMM1 expression.
Moreover, this observation was supported by data in adrenal cancer cell lines demonstrating that low responsiveness to mitotane was associated to up-modulation of RRM1 gene and that selective RRM1 silencing can restore mitotane sensitivity in vitro.
The present data are of translational relevance since they generate the hypothesis that RRM1 gene expression is a genetic marker predicting mitotane efficacy that may be used to select patients who can benefit from adjuvant mitotane therapy.
Introduction
Adrenocortical carcinoma (ACC) is a rare and aggressive malignant tumor. [1] [2] Surgery is the mainstay of therapy, [3] [4] however medical treatment has also an important role because a large proportion of ACC patients presents with metastatic disease and most of the radically resected patients relapse after surgery, often with metastases. 5 Mitotane, either as monotherapy or in combination with cytotoxic chemotherapy, is the reference drug in the management of advanced ACC. [6] [7] Mitotane has also been used in an adjuvant setting. A large retrospective multicentric study performed at several referral centers in Italy and Germany has shown that adjuvant mitotane therapy prolonged recurrence-free and overall survival in radically resected ACC patients 8 and a panel of international experts recently recommended the administration of adjuvant mitotane in all patients at high risk of relapse. 9 However, this recommendation based on retrospective data has a low level of evidence, whereas a prospective randomized controlled trial on adiuvant mitotane treatment is currently under way (www.adiuvo-trial.org).
The risk of relapse or death in ACC patients may be assessed by several parameters, including pathological features, such as mitotic index, [10] [11] [12] molecular alterations, such as TP53 mutations and beta-catenin dysregulation, 13 or immunohistochemical markers including matrix metalloproteinase type 2 (MMP-2), 14 glucose transporter 1 (GLUT1) 15 and steroidogenic factor-1 (SF-1). 16 In addition, a gene signature profile has been shown to correlate more closely with prognosis than clinical data. 17, 18 However, in contrast to the availability of prognostic parameters, very few factors predicting the efficacy of treatment have been identified. A single study reported that a low immunohistochemical expression of excision repair cross-complementation group 1 (ERCC1) correlated to objective response and overall survival in ACC patients treated with platinum-based chemotherapy. 19 Concerning mitotane treatment, attainment of drug levels in the target range of 14-20 mg/L is the only factor predicting efficacy that has been convincingly demonstrated. [20] [21] [22] Since most ACC patients are at high risk of recurrence after primary surgery applying current prognostication methods, 9 selection of patients for adjuvant therapy with mitotane based upon predictive factors for drug efficacy may represent a superior approach than selection based on prognostic markers. Such an approach is particularly appealing because mitotane therapy is a cumbersome and quite toxic treatment, that has to be maintained for years and needs frequent drug monitoring and a complex regimen of steroid replacement and management of adverse events.
5,23
We designed the present study stemming from the previous work of our research group on the role of genes involved in DNA repair or synthesis as predictors of response to chemotherapy in non-small cell lung cancer, neuroendocrine tumors and mesothelioma [24] [25] [26] and aimed to test the expression of ribonucleotide reductase large subunit 1 (RRM1) and ERCC1 genes in a cohort of ACC patients and to correlate gene expression with clinical outcome. The rationale for investigating RRM1 and ERCC1 genes as potential biomarker in ACC was based on their prognostic relevance in other cancer types 27 and on the sequential use of platinum and gemcitabine-based therapy in ACC. 28 In addition, we analyzed the predictive role of these two markers in patients treated with adjuvant mitotane and strengthened the in vivo results by in vitro analysis on ACC cell lines. In the event of unacceptable side effects, the patients were allowed to return to a lower dose or discontinue mitotane temporarily restarting with a lower dose. 
Patients and methods

Patients
Statistical analysis.
Correlation between the expression of the two gene was tested using the Spearman's method, differences of categorical variables were analyzed using the chisquare test. DFS and OS survival curves were computed using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HR) for disease progression and 
Results
Patients. Both cohorts ( characteristics. ERCC1 gene expression in normal adrenal tissues was rather low as compared to a commercially available total RNA pool, whereas RRM1 gene expression levels were comparable to reference total RNA. Moreover, the difference in RRM1 gene expression levels among normal tissues collected from paraffin blocks of different ages was in the range of 1-fold change (Figure 1) 
Discussion
Mitotane is the reference drug for treatment of advanced ACC and is increasingly adopted in an adjuvant setting. [33] [34] [35] [36] [37] Demonstration of the adrenolytic effect of mitotane dates back to the fifties of the last century when studies demonstrated that administration of the drug was able to destroy the adrenal glands in animal models 38, 39 and to inhibit steroidogenesis at different enzymatic steps. 23 However, the precise mechanism of action of mitotane remains still largely unknown, and it is generally thought that mitotane cytotoxicity is mediated through binding of the reactive acyl-chloride to mitochondrial proteins and subsequent oxidative damage through generation of free radicals. 23, 37 Recently, mitotane has been shown to sensitize H295R and SW-13 ACC cells to ionizing radiations by attenuating DNA repair and interfering with cell proliferation, 40 data suggesting that mitotane, in addition to the assumed binding to proteins and phospholipids, may interact also with DNA, as was previously demonstrated in vitro. 41 Moreover, it is known that metabolic activation is required for mitotane biological activity, 37 but its metabolic pathway and the effective role of its metabolites, as well as its target molecules in tumor cells are far from being identified.
For the first time, in the present study we provide in vitro and in vivo evidence of a relationship between RRM1 enzyme and the antineoplastic activity of mitotane in ACC.
RRM1 is an enzyme involved in the synthesis of deoxyribonucleotides for DNA synthesis and represents the cellular target for gemcitabine, being its mRNA expression and genetic variants predictive of response to gemcitabine treatment in patients with different types of cancer. 27 The present study includes two independent series of radically resected ACC patients recruited in two European countries. 35 In the overall patient population, low RRM1 gene expression was significantly associated to longer disease-free and overall survival and this contrasts with other tumor models, such as non-small cell lung cancer, where low RRM1 expression in patients treated with surgery is associated with reduced survival, whereas improved survival is observed in metastatic disease in gemcitabine-treated patients. 42 However, it should be noted that RRM1 may not be a direct target of mitotane and possible alternative molecular or metabolic interactions between mitotane and RRM1 are to be further evaluated to explain this apparent discrepancy. Moreover, in vitro analysis of control non-small cell lung cancer models showed that the anti-neoplastic mitotane efficacy as well as its effect in RRM1 gene modulation is specific for ACC cancer cell ERCC1 gene expression levels were neither prognostic nor predictive of response to mitotane in our study population. The trend to significance of greater efficacy of mitotane treatment in patients with low ERCC1 expression is, in our opinion, most probably justified by the significant correlation between RRM1 and ERCC1 gene expression levels.
Our study has certainly limitations and strengths. The retrospective nature of the study, the absence of randomization between mitotane treated and non treated patients and apparently relative small sample size might lead to unknown biases. However, when compared with the literature, our cohort seems to be quite representative for patients with stage I-III ACC and we believe -acknowledging the rarity of the disease -that the sample size is one of the strength of this study. Moreover, the inclusion of two independent cohorts from different countries favors the generalization of the present results . Although it might be surprising that less than half of the patients have been treated with mitotane in this cohort,. this may be explained by the fact that more than 80% of patients had surgery before the results of our adjuvant mitotane study have been published. 43 Another strength of this study is the consistency of data on human tumors and cell culture in vitro experiments, providing new data that may help understanding the mechanism of action of mitotane and its target molecules.
In conclusion, the present data represent the first evidence that RRM1 gene expression levels predict response to mitotane treatment in an adjuvant setting and are functionally associated to mitotane sensitivity. These findings suggest that the determination of RRM1 gene expression may be of potential clinical utility to select patients for adjuvant mitotane therapy. 
